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Summary The aim of the present study was to evaluate the clinical usefulness of the cytokeratin marker CYFRA 21-1 as a screening marker
for ovarian cancer, as a predictive marker in patients with adnexal masses and as a prognostic marker in women suffering from ovarian
cancer. In order to determine the specificity of the CYFRA 21-1 test, we have investigated CYFRA 21-1 serum levels in several benign
conditions. This retrospective study comprises 37 patients suffering from ovarian cancer FIGO stages la-Ill. Sera from patients with benign
ovarian cysts, endometriosis, peMc inflammatory disease, inflammatory bowel disease and liver cirrhosis were evaluated in 90, 10, 38, 10
and 20 cases respectively. With a sensitvity of 410% and a specificity of 95%, CYFRA 21-1 was not suitable as a screening marker for ovarian
cancer. Although CYFRA 21-1 was able to discriminate between ovarian cancer and benign adnexal tumours (univariate regression model,
P= 0.0001), CYFRA 21-1 did not reveal additional information to CA 125 in a mulftivariate regression analysis (P= 0.06). CYFRA 21-1 serum
levels were elevated in benign conditions such as liver cirrhosis, but not in endometriosis and inflammatory diseases. In ovarian cancer
patients, elevated CYFRA 21-1 serum levels before therapy were associated with a poor overall and disease-free survival (log-rank test,
P= 0.02 and log-rank test, P= 0.005 respectively). CYFRA 21-1, while obviously not suitable for screening or differential diagnosis of adnexal
masses, could be useful as an additional prognostic factor in ovarian cancer patients.
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Intermediate filaments consist of fixve different classes: desmin.
v-imentin. glial filaments. neurofilaments and cytokeratins (CKs)
(Bormer et al. 1994). Cvtokeratins are structural elements of the
cytoskeleton ofboth normal epithelia and their malignant counter-
parts. Twenty different CKs hax e been identified in human epithe-
lial tissues and have been divided into two subfamilies. basic (CK
1-8) and acidic (CK 9-20) CKs. In the surface epithelium of
the ovarx. CKs 7. 8. 18 and 19 are found (Moll et al. 1982:
Bodenmuller et al. 1994).
CKs of oxarian cancer cells and normal lining cells are iden-
tical. but there is a x ast difference in quantity. as intermediate fila-
ments are expressed in relatixely high concentrations in stronglI
proliferating, tissues (Moll et al. 1983: Sundstrom et al. 1994).
Although the biochemical pathwayvs by which soluble CK frag-
ments are formed in malignant tissues and released into the circu-
lation are not fullN understood. CK serum lexels have been widely
reported to be useful indicators of tumour activity in several
human malignancies. e.g. colorectal. prostate. breast. cervical.
pancreatic and lung, cancer (Gion et al. 1994: Kainz et al. 1994:
Plebani et al. 1993).
The serum tumour marker CYFRA 21-1 detects a fragment of
CK 19 (Pujol et al. 1995). Basically. CK 19 is expressed in all
epithelia andepithelia-derixved tissues. but it has also been detected
in other cell types. e.g. peripheral blood mononuclear cells
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(Novaes et al. 1997). CK 19 has been shoxxn to be a marker of
cytodifferentiation in the human fetal endocrine pancreas
(Bouwens et al. 1997). Elevated serum levels ofCK 19 have been
descnrbed in v-arious human malignancies. e.g. pancreatic. bladder
and cervical cancer (Kainz et al. 1995: Senga et al. 1996: Grem et
al. 1997). CYFRA 21-1 has been shoxwn to be a clinicallv valuable
prognostic and monitoringc marker in oesophageal cancer. head
and neck cancer and in non-small-cell luncg cancer (NSCLC)
(Plebamu et al. 1995: Goumas et al. 1997: Yamamoto et al. 1997).
Few data on the expression of CK 19 in ovarian cancer are avail-
able. Mobus and colleagues have reported that ovarian cancer cell
lines express large amounts of CK 19. sugaesting overexpression
of CK 19 to parallel ovarian carcinogenesis (Mobus et al. 1992:
Yanagibashi et al. 1997). To the authors' knoxwledge. no data on
serum levels ofCYFRA 21-1 in oxarian cancer have been reported
so far.
The aim of the present studv w-as to exvaluate xhether CYFRA
21-1. alone or in combination wxith CA 125. has a potential as a
screening marker in epithelial oxarian cancer. Furthermore. we
have compared preoperative serum lex els ofCYFRA 21-1 and CA
125 in patients with benign ovarian cysts and epithelial oxvarian
cancer. wxith recard to their value in the differential diarnosis of
adnexal masses. Additionallv. we hax-e inxestigated the prornostic
potential of CYFRA 21-1 serum lexels evaluated before therapy.
Serum lexels of cytokeratins are known to be elexated in several
benign conditions. e.g. inflammatorv diseases (Ouhavoun et al.
1990: Nakamura et al. 1997) and lixer disease (Sabbatini et al.
1988). To identify possible benign conditions being associated
with elex ated CYFRA 21-1 lexvels. x e have evaluated serum
samples of patients with endometriosis. pelx ic inflammator-
disease. inflammator bowel disease. lixer cirrhosis and hepatitis.
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MATERIALS AND METHODS
This retrospective study includes 175 preoperative serological
examinations of patients with clinically doubtful findings in the
small pelvis. Thirty-seven of them were suffering from ovarian
cancer FIGO stages Ia (n = 2). Ic (n = 5). II (n = 8) and III (n = 22).
Median age at the time ofdiagnosis was 57.9 (range 29-87) years.
Histologically. 12 tumours were graded as serous adenocarcinoma.
nine as mucinous adenocarcinoma. five as undifferentiated carci-
noma. three as endometrioid carcinoma. one as clear cell carci-
noma. and seven as other kinds of oxarian cancer. Benign cysts.
endometriosis and pelvic inflammatorv disease were found in 90.
10 and 38 patients respectivelv.
AdditionalIv. we haxe investigated the sera of ten and 20
patients suffering from inflammatorv bowel disease (Crohn's
disease and ulceratixe colitis) and liver cirrhosis respectively.
Serum lexvels of CYFRA 21-1 were additionally evaluated in a
panel of 40 female blood donors. All of these women were
apparently healthy and had no history of malignancy. Median age
was 31.3 (range 19-53) years.
Clinical management
All patients sufferinc from ovarian cancer under- ent total abdom-
inal hysterectomy. bilateral salpingo-oophorectomy. pelvic and
para-aortic lymphadenectomy and omentectomy. Patients with
stages lc-[II and patients with clear cell carcinoma underwent a
platinum-containing chemotherapy regimen. All patients were
followed up in 3-month interxals. including vaginorectal palpa-
tion. abdominal ultrasound examination and serum tumour marker
evaluation. The median duration of follow-up was 21.5 (range
0.5-67) months. Sixteen patients developed progressive/recurrent
disease after primary therapy. with a median time to progression of
5 (range 0-14.5) months. Sixteen patients died ofthe disease.
Serum assay
Blood samples were collected by peripheral vein puncture.
allowed to clot. centrifuged and stored in four aliquots at -80'C.
Serum concentrations of CYFRA 21-1 were measured using the
CYFRA 21-1 enzvme-linked immunosorbent assay (ELISA)
(Boehringer Mannheim. Mannheim. Germany). a two-site enzyme
immunoassay for the detection of cvtokeratin 19. The assay was
carried out according to the manufacturer's instructions. using
the automated ELISA processor ES 300 (Boehringer Mannheim).
The intra-assay coefficient ofcorrelation was 6.5%7 at a concentra-
tion of 3 igo 1-1. Serum CA 125 was measured using, an immuno-
radiometric assay (Abbott CA 125 RIA Diagnostic Kit. Abott
Laboratories. NC. USA). Variation coefficient at 46 U ml for ten
assays was 5.2%c. All tests were run in duplicate.
Statistical analysis
Because of their skewed distribution. median xvalues (range) are
gixen to describe serum CYFRA 21-1 and CA 125 levels.
Logarithmic-transformed values were used for further analysis.
Logistic regression models (Hosmer et al. 1989) were used to
analyse the influence of serum CYFRA 21-1 and CA 125 levels on
the probability of malignancy. Using a logistic regression model.
sensitivity and specificity were calculated for each possible
threshold value of estimated probabilitv for malignancy. Based on
these values. receiver operator characteristics (ROC) curxes
(Campbell et al. 1996) were constructed (Figure IA). A logistic
regression model was used to compare healthy xAomen and ovarian
cancer patients with respect to their CYFRA 21-1 xalues.
Univariate and multivariate logistic regression analyses were used
to compare patients with benign ovarian cysts and ovarian cancer
patients with respect to their CYFRA 21-1 and CA 125 values.
The ROC curves (Figure 1B) show the influence of each of the
two variables on the probability for malignancy. as well as the
diagnostic power oftheir simultaneous consideration.
Comparison of serum levels between unpaired groups were
made using the Mann-Whitney U-test. Sun ival probabilities were
calculated by the product limit method of Kaplan and Meier.
Differences betseen groups in survixal curves were assessed
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Figure 1 Receiver Operator Characteristics (ROC) curve companng (A)
healthy women (n = 40) and ovanan cancer patients (n = 37) with respect to
their preoperative CYFRA 21-1 serum levels and (B) patients with benign
ovanan cysts (n = 90) and ovarian cancer patients (n = 37) with respect to
their CYFRA 21-1 (- - -), and CA 125 (-) serum levels, and with respect to
the simultaneous consideration of both variables (--- -)
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using the log-rank test. The area under the ROC curxses and its
standard dexiation (s.d.) are gixen (DeLong et al. 1988). P < 0.05
xxas considered statistically significant. We used the SAS statis-
tical software svstem (SAS Institute. Car>. NC. USA) to carry out
calculations.
RESULTS
Serum CYFRA 21-1 and the presence of ovarian cancer
compared with healthy women
The overall median serum level of CYFRA 21-1 xxas 1.6 (rangre
0.4-54.9) jg 1-1. Median serum levels in healthv controls. in
benign ovarian cysts and in ovarian cancer were 1.9 (ranae
0.1-11.0) gcg 1-'. 1.3 (rancge 0.4-20.3) jgc 1-' and 2.4 (rance
0.9-54.9) jci 1-' respectively. A univariate logistic regression
model rexealed that CYFRA 21-1 had a significant influence on
the risk of presentina with malicgnancy (P = 0.04). The higher the
CYFRA 21-1 serum level. the hicher was the relative risk of
presenting wxith malignancy. At 4.7 jci 1-'. CYFRA 21-1 achieved
a sensitivity of 41%'c and a specificitv of 95%c. A ROC curn-e
comparing healthy women (n = 40) and ovarian cancer patients
(n = 37) xxith respect to their preoperatixe CYFRA 21-1 serum
levels is shown in Fiuure IA. The area under the ROC curxe wxas
0.53 (s.d. 0.078).
Preoperative CYFRA 21-1 serum levels as prognostic
factors in ovarian cancer
As CYFRA 21-1 lacks a clearix defined cut-off value. a cut-off
x-alue of 9.4 jgc 1-1 was selected according to the 0.75 quantile
(upper quartile) of serum concentrations measured in the panel of
ox anan cancer patients (Obermair et al. 1997). Using the product
limit method ofKaplan and Meier. w-e calculated the probability of
pretreatment CYFRA 21-1 serum lexels to predict the overall
survival. Elevated CYFRA 21-1 serum levels before therapyxwere
associated with a poor overall and disease-free surnix-al (log-rank
test. P = 0.02. Fioure 2: and log-rank test. P = 0.005. Figure 3.
respectively). Patients with and xxithout elevated CYFRA 21-1
serum levels did not show statistically significant differences
regardincg treatment modality. performance status. mean age of the
patients and distribution oftumour stage.
CYFRA 21-1 and CA 125 serum levels in benign
conditions
Serum levels of CYFRA 21-1 and CA 125 in pelvic inflammatorx
disease. endometriosis. liver cirrhosis and inflammatorx bowel
disease are shown in Table 1. Compared with normal controls.
median serum lexels of CYFRA 21-1 were found to be signifi-
cantly elexated in patients with lixer cirrhosis (Mann-Whitnev U-
test. P = 0.0001). but not in patients with pelvic inflammatory
disease. endometriosis and inflammatorv bowxel disease.
Serum CYFRA 21-1 and CA 125 and the presence of
ovarian cancer compared with benign cysts
The overall median serum level of CA 125 was 24.7 (rance 3.1-
19 619) U m'. Median CA 125 serum levels in patients xxith
benign cysts and oxarian cancer were 17.3 (rance 3.1-1340) U ml
and 293 (rangre 14.8-19 619) U ml respectivelv. In a univariate
logistic regression model. CYFRA 21-1 and CA 125 predicted the
presence ofmalignancy as opposed to benign cysts (P =0.0001 and
P = 0.0001 respectively). In a multivariate regression analysis
considering serum CYFRA 21-1 and CA 125 levels simultane-
ously. only CA 125. but not CYFRA 1-1. revealed statistical
significance (P = 0.0001 and P = 0.06 respectively). A ROC curve
comparinr patients with benign oxanan cysts (n = 90) and oxarian
cancer patients (n=37) xxith respect to their CYFRA 21-1 and
CA 125 serum lexels in a multivanrate loristic re,ression analysis
for CYFRA 21-1. CA 125 and simultaneous consideration of both
xariables is shown in Figure lB. The areas under the ROC curves
were 0.86 (s.d. 0.038). 0.93 (s.d. 0.027) and 0.95 (s.d. 0.023)
respectively.
Correlation of CYFRA 21-1 serum levels in ovarian
cancer with CA 125 serum levels, tumour stage, lymph
node involvement, histological type, histological grade,
extent of residual disease and age at the time of
diagnosis
AWhen serum lexels of CYFRA 2 1-1. taken before therapy. were
grouped by CA 125 serum lexvels. tumour stage. lymph node
involxement. histological type. histological grade. extent of
residual disease and age at the time of diagnosis. e found no
statistically significant associations xxith the investigated clinico-
pathological parameters.
DISCUSSION
Although cvtokeratin tumour markers have been investigated in a
wide ariety of human malignancies. fexx data on cytokeratins in
ovanan cancer exist.
In the present study. serum CYFRA 21-1 showxed a sensitivitx of
41 %7 and a specificity of95% in ovarian cancer patients. The ROC
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Figure 2 Kaplan-Meier analysis regarding overall survival of ovarian
cancer patients with CYFRA 21-1 serum levels above the cut-off level
(9.4Ftg 1; n =9) and CYFRA 21-1 serum levels below the cut-off level
(9.4 pg V., n = 28)
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FKgure 3 Kaplan-Meer analysis regarding disease-free survival of ovanan
cancer patents with CYFRA 21-1 serum levels above Mte cut-off level
(9.4jig h1; n = 9) and CYFRA 21-1 serum levels below the cut-off level
(9.4 jg 1-1: n = 28)
curxe shows that CYFRA ' 1-1 is not suitable as a screening
marker forovarian cancer. Gixen the low prex alence ofthe disease
(50/100 000). the CYFRA 21-1 test would yield only 1 in 245
wxomen with a positive test actuallv havIing the disease.
With respect to differential diagnosis of adnexal masses.
elevated CYFRA 21-1 serum levels sho%ved a positive correlation
with the risk ofpresenting with malionant disease. The higher the
CYFRA 21-1 lexels. the higher was the risk of carrying a mali-
nant oxarian cyst. This points to the fact that cytokeratin release is
a genuine part ofovarian cancer dexelopment. Howexer. our study
also shows that CYFRA 21-1 does not reveal additional diagnostic
information in the presence of the established tumour marker CA
125. This documents that CYFRA 21-1 is not clinically useful as
an additional discriminator between the absence or presence of
malignancy in patients intended to undergo surgery for suspicious
ox arian c sts.
It has to be stressed that all tumour marker results haxe to be
interpreted wxith caution. Even CA 125. which is generallv estab-
lished as a specific tumour marker for oxarian cancer. has been
reported to be elexated in xvarious benign conditions as well as in
other malignancies. e.g. endometriosis and endometrial cancer
(Kramer et al. 1993: Rose et al. 1994). This is also true for cxto-
keratins. which haxe been reported to be elevated in a wide xariety
of human malignancies (Gion et al. 1994: Sliutz et al. 1995). This
fact is based on the abundant expression ofcytokeratins. wAhich are
found in all epithelia and epithelia-derived tissues. Thus. cvtoker-
atins or cvtokeratin fragments are expressed in large quantities in
all proliferating epithelial tissues. Diseases of the liver hax-e been
reported to be associated with elexated serum lexels of cytoker-
atins (Sabbatini et al. 1988). This is consistent with our findings of
elex ated CYFRA 21-1 serum levels in patients wxith lix-er cirrhosis.
When interpreting elex ated CYFRA 21-1 serum lexels. it has to be
taken into account that CYFRA 21-1 is not a specific ovarian
cancer tumour marker and that the coincidence of other bemnin
diseases or malignancies may lead to elexated serum lexels and
consequentlI to false-positix e test results.
CK 19 has been described as an indicator ofepithelial injuries in
inflammatory diseases. e.g. parodontosis and chronic bronchitis
(Ouhayoun et al. 1990: Nakamura et al. 1997). In the present
study. CYFRA 21-1 was not increased in inflammatory bowel
disease or pelxvic inflammatory disease. This indicates that inflam-
mation per se is not sufficient to cause elevated CK levels.
In the present study. we found no correlation between CYFRA
21-1 serum lexvels and tumour staae. This finding supports the
assumption that serum lexels of cytokeratins are not reflective of
the tumour bulk but rather indicative of strongly proliferating,
tumours (Bormer et al. 1994).
Elevated serum levels of cvtokeratins have been shown to
provide prognostic information in several malignancies (Kainz et
al. 1994: Carpelan-Holmstrom et al. 1996). In our study. we found
that increased CYFRA 21-1 serum levels before therapy are
predictive ofthe patients' outcome in oxarian cancer. Patients x ith
elexated CYFRA 21-1 serum lexels had a shortened oxerall and
disease-free surxvival. Additional studies with an increased number
of patients are justified to clarifx further the prognostic value of
CYFRA 21-1 in ovarian cancer patients.
Table 1 Median serum levels of CYFRA 21-1 and CA 125 in patients with ovanan cancer. benign
ovanan cysts, pelvic inflammatory disease. endometnosis, inflammatory bowel disease. liver cirrhosis
and in healthy control subjects
No. Median serum levels Median serum levels
of CYFRA 21-1 of CA 125
uG tI- (range) u [' (range)
Ovanan Cancer 37 2.4 (0.9-54.9) 293 (14.8-19619)
Benign ovaian cysts 90 1.3 (0.4-20.3) 17.3 (3.1-1340)
Pelvic inflammatory 38 1.3 (0.4-3.4) 18.8 (4.9-361)
disease
Endornetriosis 10 1 0 (0.7-1.8) 62.9 (9.4-374)
Inflammatory bowel 10 2.1 (1.3-5.6) 14.3(4.6-40.6)
disease
Liver cirrhosis 20 4.7 (1 9-8.2) 293 (12.3-8546)
Healthy controls 40 1.9 (0.1-11) -
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In conclusion. our data indicate that CYFRA 21-1 is suitable
neither as a screening marker nor as an additional tool fordifferen-
tial diagnosis of adnexal masses. Regarding benign diseases.
patients with liver cirrhosis show extremely high cytokeratin
levels. whereas inflammatory conditions are not invariably associ-
ated with elevated serum levels ofCYFRA 21-1. In ovarian cancer
patients. serum levels ofCYFRA 21-1 are not associated with clin-
icopathological parameters. The most promising result of this
study is the prognostic value of preoperative CYFRA 21-1 serum
levels regarding overall and disease-free survival. Considering
these results. CYFRA 21-1. while obviously not suitable for
screening or differential diagnosis of adnexal masses. could be
useful as an additional prognostic factor in ovarian cancerpatients.
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